Avrobio (NASDAQ:AVRO) received a $40.00 target price from equities researchers at HC Wainwright in a note issued to investors on Tuesday, TipRanks reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 117.39% from the company’s current price.
Several other analysts also recently weighed in on the stock. Cowen reissued a “buy” rating on shares of Avrobio in a research report on Thursday, May 2nd. Janney Montgomery Scott initiated coverage on shares of Avrobio in a research report on Friday, April 5th. They set a “buy” rating and a $24.42 target price on the stock. Leerink Swann dropped their target price on shares of Avrobio from $27.00 to $19.00 and set a “market perform” rating on the stock in a research report on Thursday, January 17th. Finally, Zacks Investment Research downgraded shares of Avrobio from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $31.06.
NASDAQ:AVRO opened at $18.40 on Tuesday. The company has a market cap of $461.71 million and a price-to-earnings ratio of -5.08. Avrobio has a twelve month low of $11.85 and a twelve month high of $53.70.
Avrobio (NASDAQ:AVRO) last released its earnings results on Monday, May 13th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.01). As a group, equities analysts expect that Avrobio will post -2.77 earnings per share for the current year.
In other news, insider Geoffrey Mackay sold 14,000 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $27.25, for a total value of $381,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christopher Paige sold 10,000 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $25.72, for a total transaction of $257,200.00. The disclosure for this sale can be found here. 4.70% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new stake in Avrobio during the third quarter worth $48,000. Pictet Asset Management Ltd. boosted its holdings in Avrobio by 0.9% during the first quarter. Pictet Asset Management Ltd. now owns 168,574 shares of the company’s stock worth $3,717,000 after buying an additional 1,543 shares in the last quarter. Great West Life Assurance Co. Can purchased a new stake in Avrobio during the fourth quarter worth $34,000. Northern Trust Corp boosted its holdings in Avrobio by 2.8% during the fourth quarter. Northern Trust Corp now owns 79,211 shares of the company’s stock worth $1,319,000 after buying an additional 2,170 shares in the last quarter. Finally, Emerald Advisers LLC boosted its holdings in Avrobio by 0.6% during the fourth quarter. Emerald Advisers LLC now owns 380,636 shares of the company’s stock worth $6,338,000 after buying an additional 2,262 shares in the last quarter. 73.82% of the stock is currently owned by institutional investors and hedge funds.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.